Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 9/20 | 0.54 |
| ▸ | TYMS | P04818 | 4/20 | 0.54 |
| ▸ | GART | P22102 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | ATIC | P31939 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | TLR4 | O00206 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053297 | 0.92 | DHFR (0.54) | DHFRTYMSGARTKDM4EMEN1 | |
| SCHEMBL5549456 | 0.88 | DHFR (0.53) | DHFRTYMSGARTKDM4EMEN1 | |
| SCHEMBL338037 | 0.88 | DHFR (0.57) | DHFRTYMSGARTKDM4EMEN1 | |
| Methopterine SCHEMBL2274614 | 0.87 | DHFR (0.69) | DHFRTYMSGARTKDM4EMEN1 | |
| SCHEMBL25167471 | 0.87 | DHFR (0.57) | DHFRTYMSGARTKDM4EMEN1 | |
| SCHEMBL28344641 | 0.87 | DHFR (0.57) | DHFRTYMSGARTKDM4EMEN1 | |
| SCHEMBL28135233 | 0.87 | DHFR (0.57) | DHFRTYMSGARTKDM4EMEN1 | |
| SCHEMBL20486467 | 0.87 | DHFR (0.57) | DHFRTYMSGARTKDM4EMEN1 | |
| SCHEMBL869876 | 0.87 | DHFR (0.57) | DHFRTYMSGARTKDM4EMEN1 | |
| SCHEMBL16583122 | 0.87 | DHFR (0.57) | DHFRTYMSGARTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188738-B2 | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract | Université Libre de Bruxelles (BE) | 2019-01-29 | — | — | US | disclosed |
| US-20160263232-A1 | Formulations Useful in the Treatment of Proliferative Diseases Affecting the Respiratory Tract | UNIVERSITE LIBRE DE BRUXELLES (BE) | 2016-09-15 | — | — | US | disclosed |
| EP-3057619-A1 | FORMULATIONS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES AFFECTING THE RESPIRATORY TRACT | Université Libre de Bruxelles (BE) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015055796-A1 | FORMULATIONS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES AFFECTING THE RESPIRATORY TRACT | Université Libre de Bruxelles (BE) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188738-B2 | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract | FOLR1, FOLR2, FGFR1 | DHFR 8/4885TYMS 173/4885GART 1028/4885 |
| US-20160263232-A1 | Formulations Useful in the Treatment of Proliferative Diseases Affecting the Respiratory Tract | FOLR1, FOLR2, FGFR1 | DHFR 8/4885TYMS 173/4885GART 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.